Lamivudine: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk (New page: {{subpages}} right|thumb|100px|{{#ifexist:Template:Lamivudine structure.jpg/credit|{{Lamivudine structure.jpg/credit}}<br/>|}}Lamivudine '''Lamivudine'...) |
imported>David E. Volk m (→External links) |
||
Line 24: | Line 24: | ||
== External links == | == External links == | ||
*{{DailyMed}} | * {{DailyMed}} | ||
* | * {{MedMaster}} | ||
* {{DrugBank}} |
Revision as of 12:36, 5 March 2008
![](http://s9.addthis.com/button1-share.gif)
Lamivudine is a nucleotide-based reverse transcriptase inhibitor used to treat HIV/AIDS and hepatitis B virus. It is an analog of zalcitabine that competes, in the triphosphate form, for incorporation in viral DNA with cytosine triphosphate. Lacking a 3'-OH group, it terminates DNA chain elongation because the phosphodiester bond necessary for elongation cannot be made.
Its IUPAC name is 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one and it has chemical formula C8H11N3O3S.
Brand names
single drug brand names
- 3TC
- Epivir
- Epivir-HBV
- Hepitec
- Heptovir
- Zeffix
brand mixtures
- Combivir (Lamivudine + Zidovudine)
- Kivexa (Abacavir (Abacavir Sulfate) + Lamivudine)
- Trizivir (Abacavir (Abacavir Sulfate) + Lamivudine + Zidovudine)
External links
- Lamivudine - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Template:MedMaster
- Template:DrugBank